David E Kandzari

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Comparison of long-term (seven year) outcomes among patients undergoing percutaneous coronary revascularization with versus without stenting
    David E Kandzari
    Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 97:1467-72. 2006
  2. ncbi request reprint Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Interv Cardiol 19:405-13. 2006
  3. ncbi request reprint Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes
    David E Kandzari
    Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 96:750-5. 2005
  4. ncbi request reprint Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction
    David E Kandzari
    Department of Medicine, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 151:1288-95. 2006
  5. ncbi request reprint Procedural and clinical outcomes with catheter-based plaque excision in critical limb ischemia
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Endovasc Ther 13:12-22. 2006
  6. ncbi request reprint Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 48:2440-7. 2006
  7. ncbi request reprint Drug-eluting stent thrombosis: it's never too late
    David E Kandzari
    Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA
    Nat Clin Pract Cardiovasc Med 3:638-9. 2006
  8. ncbi request reprint Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes
    David E Kandzari
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 149:474-81. 2005
  9. ncbi request reprint Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial
    James E Tcheng
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Circulation 108:1316-23. 2003
  10. ncbi request reprint Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation
    Eric L Eisenstein
    Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    JAMA 297:159-68. 2007

Detail Information

Publications65

  1. ncbi request reprint Comparison of long-term (seven year) outcomes among patients undergoing percutaneous coronary revascularization with versus without stenting
    David E Kandzari
    Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 97:1467-72. 2006
    ..In conclusion, compared with angioplasty alone, revascularization with coronary stents provides a significant early and sustained decrease in the need for repeat revascularization, but stents do not influence long-term survival...
  2. ncbi request reprint Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Interv Cardiol 19:405-13. 2006
    ..This review describes the pharmacology and design on the Endeavor stent, summarizes results from recent clinical trials evaluating the Endeavor stent, and provides an overview of ongoing and future directions for clinical investigation...
  3. ncbi request reprint Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes
    David E Kandzari
    Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 96:750-5. 2005
    ....
  4. ncbi request reprint Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction
    David E Kandzari
    Department of Medicine, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 151:1288-95. 2006
    ..We examined the infarct artery-specific impact of epicardial and myocardial flow and reperfusion after primary PCI for acute myocardial infarction...
  5. ncbi request reprint Procedural and clinical outcomes with catheter-based plaque excision in critical limb ischemia
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Endovasc Ther 13:12-22. 2006
    ..To examine the safety and efficacy of catheter-based plaque excision as an alternative therapy to surgery, conventional angioplasty, and/or stenting in high-risk patients with critical limb ischemia (CLI)...
  6. ncbi request reprint Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 48:2440-7. 2006
    ..This trial examined the relative clinical efficacy, angiographic outcomes, and safety of zotarolimus-eluting coronary stents (ZES) with a phosphorylcholine polymer versus sirolimus-eluting stents (SES)...
  7. ncbi request reprint Drug-eluting stent thrombosis: it's never too late
    David E Kandzari
    Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA
    Nat Clin Pract Cardiovasc Med 3:638-9. 2006
  8. ncbi request reprint Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes
    David E Kandzari
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 149:474-81. 2005
    ....
  9. ncbi request reprint Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial
    James E Tcheng
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Circulation 108:1316-23. 2003
    ..However, variations in trial designs, modest sample sizes, and limited long-term follow-up have precluded these studies from being definitive...
  10. ncbi request reprint Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation
    Eric L Eisenstein
    Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    JAMA 297:159-68. 2007
    ..Recent studies of drug-eluting intracoronary stents suggest that current antiplatelet regimens may not be sufficient to prevent late stent thrombosis...
  11. ncbi request reprint Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials
    David E Kandzari
    Division of Cardiology, Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 147:457-62. 2004
    ....
  12. ncbi request reprint Late thrombosis following treatment of in-stent restenosis with drug-eluting stents after discontinuation of antiplatelet therapy
    Richard E Waters
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA
    Catheter Cardiovasc Interv 65:520-4. 2005
    ..Further studies are necessary to better define the associated risk and ideal duration of antiplatelet therapy necessary in this cohort of patients with restenotic lesions...
  13. ncbi request reprint Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial)
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 92:779-84. 2003
    ..Hospitalizations after primary PCI are so short, however, that efforts to accelerate discharge with abciximab appear unfeasible, and overall costs remain unchanged...
  14. ncbi request reprint Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 94:1029-33. 2004
    ..We examined the effect of aspirin use at the time of admission and discharge from a large-scale, prospective multicenter trial of patients who had been treated with primary percutaneous coronary intervention in acute myocardial infarction...
  15. ncbi request reprint Temporal trends in target vessel revascularization in clinical practice: long-term outcomes following coronary stenting from the Duke Database for Cardiovascular Disease
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Invasive Cardiol 18:398-402. 2006
    ..We examined outcomes of clinical restenosis and temporal trends in repeat target vessel revascularization (TVR) among a broad, unselected patient population undergoing percutaneous coronary revascularization...
  16. doi request reprint Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary
    Eric L Eisenstein
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    JACC Cardiovasc Interv 2:1199-207. 2009
    ....
  17. ncbi request reprint Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 44:2133-6. 2004
    ..We examined clinical outcomes in the Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment (ISAR-REACT) trial based on the duration of pretreatment with a 600-mg loading dose of clopidogrel...
  18. doi request reprint Comparison by meta-analysis of drug-eluting stents and bare metal stents for saphenous vein graft intervention
    Michael S Lee
    Division of Cardiology, University of California, Los Angeles, CA, USA
    Am J Cardiol 105:1076-82. 2010
    ..49 to 0.99). No differences were found in the risk of death (OR 0.78, 95% CI 0.59 to 1.02) or stent thrombosis (OR 0.41, 95% CI 0.15 to 1.11) between the 2 groups. In conclusion, these findings support the use of DESs in SVG lesions...
  19. ncbi request reprint Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions
    David F Kong
    Division of Cardiology, Department of Medicine, Duke University Medical Center and Clinical Research Institute, Durham, NC 27710, USA
    Am J Cardiol 92:651-5. 2003
    ..There also is increasing evidence that mortality reductions are preserved at 6 months...
  20. ncbi request reprint Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction
    David E Kandzari
    Interventional Cardiology and Genomic Sciences, Duke Clinical Research Institute, Durham, North Carolina, USA
    Rev Cardiovasc Med 7:S29-37. 2006
    ..This review summarizes the current status of pharmacologic and invasive strategies for the treatment of STEMI and describes recent and ongoing directions for clinical investigation...
  21. doi request reprint Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity
    Colin M Barker
    Division of Cardiology, University of Texas Medical School at Houston, Houston, Texas 77030, USA
    JACC Cardiovasc Interv 3:1001-7. 2010
    ..The objective of this study was to evaluate the antiplatelet effect of clopidogrel 150 mg/day in patients with high on-treatment reactivity (OTR) and to further assess this effect according to CYP2C19 genotype...
  22. ncbi request reprint Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation
    L Kristin Newby
    Duke Clinical Research Institute and the Duke Centers for Education and Research on Therapeutics CERTs, Durham, NC 27715 7969, USA
    J Thromb Thrombolysis 16:119-28. 2003
    ..While aspirin's secondary prevention benefit is clear, prior reports indicate that 19-83% of eligible patients may not use aspirin chronically...
  23. ncbi request reprint Peripheral arterial disease: an overview of endovascular therapies and contemporary treatment strategies
    Kanwar P Singh
    Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA
    Rev Cardiovasc Med 7:55-68. 2006
    ..The current standard of care for significant carotid artery stenosis can include carotid stenting and carotid endarterectomy, but medical therapy may have a role also...
  24. ncbi request reprint The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention
    Charles E Mayes
    Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, 27710, USA
    J Invasive Cardiol 14:36E-46E; quiz 47E. 2002
    ....
  25. ncbi request reprint Seeking the optimal aspirin dose in acute coronary syndromes
    David F Kong
    Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 90:622-5. 2002
  26. ncbi request reprint Present and evolving role of eptifibatide in the treatment of acute coronary syndromes
    Pierluigi Tricoci
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Expert Rev Cardiovasc Ther 5:401-12. 2007
    ....
  27. ncbi request reprint Current concepts in the antithrombotic management of non-ST-elevation acute coronary syndromes
    David E Kandzari
    Division of Cardiology, Duke Clinical Research Unit, 2400 Pratt Street, Room 7063, Durham, NC 27705, USA
    Curr Cardiol Rep 6:279-86. 2004
    ..This review provides a pathophysiologic rationale for antithrombotic therapies in ACS, examines the results of recent trials, and presents future directions for clinical investigation...
  28. pmc The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial
    John P Vavalle
    Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 162:996-1002. 2011
    ..Eptifibatide dosing is weight adjusted for patients up to 121 kg. Patients above this weight receive the same maximal dose, although it is unknown if this provides adequate eptifibatide concentration or platelet inhibition...
  29. ncbi request reprint Integrating GP IIb/IIIa inhibition into treatment strategies for acute ST-elevation myocardial infarction
    David E Kandzari
    Duke University Medical Center, Durham, NC 27710, USA
    J Invasive Cardiol 14:565-74. 2002
  30. ncbi request reprint MC-1 (pyridoxal 5'-phosphate): novel therapeutic applications to reduce ischaemic injury
    David E Kandzari
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Expert Opin Investig Drugs 14:1435-42. 2005
    ..These forthcoming evaluations should clarify the safety and efficacy of MC-1 and improve the understanding regarding its potential therapeutic role in a variety of clinical settings and indications...
  31. ncbi request reprint Coronary artery stents: evaluating new designs for contemporary percutaneous intervention
    David E Kandzari
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    Catheter Cardiovasc Interv 56:562-76. 2002
    ..The purpose of this review is to describe recent developments in stent design, examine the results of clinical trials of contemporary stents, and present future directions for investigation of new stent technologies...
  32. ncbi request reprint Clinical and angiographic efficacy of a self-expanding nitinol stent in saphenous vein graft atherosclerotic disease: the Stent Comparative Restenosis (SCORES) Saphenous Vein Graft Registry
    David E Kandzari
    Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 145:868-74. 2003
    ..The Stent Comparative Restenosis (SCORES) Saphenous Vein Graft (SVG) Registry was a multicenter, prospective registry designed to evaluate the safety and efficacy of a self-expanding, nickel-titanium (nitinol) stent for de novo SVG lesions...
  33. ncbi request reprint TARGET versus GUSTO-IV: appropriate use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and percutaneous coronary intervention
    David E Kandzari
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Cardiol 17:332-9. 2002
    ....
  34. ncbi request reprint Inflammation, platelets, and glycoprotein IIb/IIIa inhibitors
    Pascal J Goldschmidt-Clermont
    Division of Cardiology, Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, 27710, USA
    J Invasive Cardiol 14:18E-25E; quiz 26E. 2002
    ....
  35. ncbi request reprint Highlights from the American Heart Association annual scientific sessions 2001: November 11 to 14, 2001
    David E Kandzari
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 143:217-28. 2002
  36. ncbi request reprint Percutaneous recanalization of chronically occluded coronary arteries: procedural techniques, devices, and results
    Gregg W Stone
    Division of Cardiology, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10022, USA
    Catheter Cardiovasc Interv 66:217-36. 2005
  37. ncbi request reprint Catheter-based revascularization of the hepatic artery to treat coronary steal from a gastroepiploic artery bypass graft
    David E Kandzari
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    J Invasive Cardiol 15:591-3. 2003
    ..This report describes successful angioplasty and stenting of the hepatic artery to salvage the gastroepiploic bypass graft and resolve the patient s ischemic symptoms...
  38. ncbi request reprint Acute myocardial infarction: safety of cardiac MR imaging after percutaneous revascularization with stents
    Manesh R Patel
    Cardiovascular Magnetic Resonance Center and Clinical Research Institute, Duke University Medical Center, 2400 Pratt St, Durham, NC 27705, USA
    Radiology 240:674-80. 2006
    ..To retrospectively determine the safety of cardiac magnetic resonance (MR) imaging performed early (<14 days) after coronary stent implantation in patients with acute myocardial infarction (AMI)...
  39. ncbi request reprint Anticoagulation in the cath lab: a contemporary approach. Introduction
    David E Kandzari
    Interventional Cardiology and Genomic Sciences, Duke Clinical Research Institute, Durham, North Carolina, USA
    Rev Cardiovasc Med 7:S1-2. 2006
  40. ncbi request reprint Future perspectives on antithrombin and antiplatelet therapies: novel antiplatelet and antithrombin therapies
    David E Kandzari
    Interventional Cardiology and Genomic Sciences, Duke Clinical Research Institute, Durham, North Carolina, USA
    Rev Cardiovasc Med 7:S43-52. 2006
    ....
  41. ncbi request reprint The challenges of chronic total coronary occlusions: an old problem in a new perspective
    David E Kandzari
    Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, U S A
    J Interv Cardiol 17:259-67. 2004
    ..This review of total coronary occlusions provides an overview of CTO pathophysiology, describes the procedural and clinical outcomes associated with CTO revascularization, and presents future directions for clinical investigation...
  42. ncbi request reprint Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial)
    David E Kandzari
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am J Cardiol 92:660-4. 2003
    ..These results support the evaluation of MC-1 in pivotal trials of patients at risk for developing myocardial ischemia, infarction, or reperfusion injury...
  43. ncbi request reprint Experience with glycoprotein IIb/IIIa antagonists in patients with acute coronary syndromes
    David E Kandzari
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Interv Cardiol 15:121-9. 2002
  44. ncbi request reprint Contrast nephropathy : an evidence-based approach to prevention
    David E Kandzari
    Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiovasc Drugs 3:395-405. 2003
    ..Our purpose is to review the contemporary literature regarding contrast-induced renal dysfunction and present an evidence-based approach for prevention of this complication...
  45. ncbi request reprint The thrill is gone: catheter-based exclusion of a posttraumatic arteriovenous fistula with a covered stent graft
    Abdul R Halabi
    Division of Cardiology, Duke University Medical Center, Durham, NC 27705, USA
    Catheter Cardiovasc Interv 66:27-33. 2005
    ..No clinical symptom recurrence was documented at a 9-month follow-up visit...
  46. ncbi request reprint Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study)
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 93:636-9. 2004
    ..5 degrees C) and was well tolerated, which supports the evaluation of adjunctive hypothermia in pivotal trials to limit infarct size and decrease reperfusion injury...
  47. ncbi request reprint Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial)
    David E Kandzari
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 93:458-61. 2004
    ..4, 95% confidence interval 1.2 to 10.2). Because facial or head trauma may greatly influence treatment decisions, this risk factor should be incorporated into models designed to estimate the risks and benefits of fibrinolytic therapy...
  48. ncbi request reprint An anomalous left coronary artery originating from the pulmonary artery in a 72-year-old woman: diagnosis by color flow myocardial blush and coronary arteriography
    David E Kandzari
    Division of Cardiology, Duke University Medical Center, Box 31203, Durham, NC 27710, USA
    J Invasive Cardiol 14:96-9. 2002
    ....
  49. doi request reprint The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions
    Sunil V Rao
    The Duke Clinical Research Institute, Durham, NC, USA
    J Am Coll Cardiol 55:2187-95. 2010
    ..Finally, we describe potential directions for future investigation in the transradial realm...
  50. ncbi request reprint The bent stent
    Can M Nguyen
    Division of Cardiology, P O Box 3850, Duke University Medical Center, Durham, NC 27710, USA
    J Invasive Cardiol 14:54-6. 2002
  51. ncbi request reprint Radiocontrast nephropathy: a time for affirmative action
    Abdallah G Rebeiz
    Duke University Medical Center, P O Box 3157, Durham, NC, 27710, USA
    J Invasive Cardiol 15:23-5. 2003
  52. ncbi request reprint The VB-1 catheter: a novel catheter for peripheral arterial revascularization
    David E Kandzari
    Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Catheter Cardiovasc Interv 59:514-7. 2003
    ..This report describes the adaptation of the Behar Internal Mammary VB-1 catheter for peripheral revascularization procedures in patients with complex anatomy not amendable to other conventional peripheral guide catheters...
  53. doi request reprint Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials
    Stuart J Pocock
    London School of Hygiene and Tropical Medicine, London, United Kingdom
    J Am Coll Cardiol 51:23-32. 2008
    ..We sought to validate 4 angiographic measures as potential surrogates for clinical restenosis (target lesion revascularization [TLR]) after stent implantation...
  54. ncbi request reprint Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients
    Anthony Gershlick
    University Hospitals of Leicester School of Medicine, Leicester, United Kingdom
    Am J Cardiol 100:45M-55M. 2007
    ....
  55. ncbi request reprint Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III
    Akiyoshi Miyazawa
    Stanford University Medical Center, Stanford, CA 94305, USA
    Am Heart J 155:108-13. 2008
    ..The purpose of this study was to investigate the vascular response of zotarolimus-eluting stent (ZES) and sirolimus-eluting stent (SES) using serial intravascular ultrasound (IVUS)...
  56. ncbi request reprint Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study
    Jean Claude Tardif
    Montreal Heart Institute, Montreal, Canada
    J Thorac Cardiovasc Surg 133:1604-11. 2007
    ..The MEND-CABG trial tested the hypothesis that MC-1 reduces cardiovascular morbidity and mortality after coronary artery bypass graft...
  57. ncbi request reprint Aspirin dose and six-month outcome after an acute coronary syndrome
    Martin J Quinn
    St Vincents University Hospital, Dublin, Ireland
    J Am Coll Cardiol 43:972-8. 2004
    ..This study was designed to compare the efficacy of low and intermediate aspirin doses in acute coronary syndromes...
  58. ncbi request reprint Mechanism of luminal gain with plaque excision in atherosclerotic coronary and peripheral arteries: assessment by histology and intravascular ultrasound
    Fumiaki Ikeno
    Stanford University Medical Center, Stanford, CA, USA
    J Interv Cardiol 20:107-13. 2007
    ....
  59. ncbi request reprint Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction
    Paul Sorajja
    The Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Eur Heart J 26:667-74. 2005
    ..We sought to determine whether the combination of SigmaSTR and MB after primary percutaneous coronary intervention (PCI) in AMI has greater prognostic utility than either measure alone...
  60. ncbi request reprint Double negatives
    David E Kandzari
    Am Heart J 145:9-11. 2003
  61. ncbi request reprint Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I
    Gregg W Stone
    Columbia University Medical Center, Cardiovascular Research Foundation, New York, NY 10022, USA
    Circulation 112:2364-72. 2005
  62. ncbi request reprint Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II
    Gregg W Stone
    Columbia University Medical Center, The Cardiovascular Research Foundation, New York, NY 10022, USA
    Circulation 112:2530-7. 2005
  63. ncbi request reprint Intracoronary brachytherapy: time to sell short?
    David E Kandzari
    Circulation 106:646-8. 2002
  64. ncbi request reprint Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease
    Paul Michael Grossman
    University of Michigan Healthcare System, Ann Arbor, MI 48109 0311, USA
    Am Heart J 153:874-80. 2007
    ....
  65. ncbi request reprint Making positive out of negative trials
    David E Kandzari
    Am Heart J 143:950-1. 2002